Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

ConclusionIn conjunction with ALK mutation, the expression of this proteomic signature may represent a liquid biopsy-based marker of long-term response to crizotinib in NSCLC. Expanding the utility of prognostic biomarkers of response duration could influence choice of therapy, therapeutic sequencing, and potentially the need for alternative or combination therapy.Trial registration ClinicalTrials.gov, NCT02041468. Registered 22 January 2014,https://clinicaltrials.gov/ct2/show/NCT02041468?term=NCT02041468&rank=1
Source: Clinical Proteomics - Category: Biochemistry Source Type: research